JJ
GYRE icon

Johnson & Johnson’s Gyre Therapeutics GYRE Stock Holding History

Johnson & Johnson’s Portfolio GYRE Stock Details GYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,463
Closed -$32.3K – 24
2023
Q3 		$32.3K Hold
4,463
– – 0.01% 23
2023
Q2 		$23.5K Hold
4,463
– – 0.01% 22
2023
Q1 		$13.9K Sell
4,463
-4,464
-50% -$17K ﹤0.01% 23
2022
Q4 		$35K Hold
8,927
– – 0.01% 21
2022
Q3 		$34K Hold
8,927
– – 0.01% 22
2022
Q2 		$119K Hold
8,927
– – 0.03% 20
2022
Q1 		$44K Hold
8,927
– – 0.01% 22
2021
Q4 		$61K Hold
8,927
– – 0.01% 24
2021
Q3 		$275K Buy
+8,927
New +$294K 0.02% 21

Other funds holding GYRE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Johnson & Johnson's GYRE Position: Q4 2023 in Review

Johnson & Johnson sold out of Gyre Therapeutics (GYRE) in Q4 2023, closing a stake of 4,463 shares — an estimated $32.3K sold.

Johnson & Johnson first reported a position in GYRE in Q3 2021 and held it in 9 quarters. The position peaked at $275K in Q3 2021. 16 funds tracked by Wall St. Rank hold GYRE as of Q4 2023.

  • Johnson & Johnson reported no remaining Gyre Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Johnson & Johnson sold 4,463 Gyre Therapeutics shares in Q4 2023, an estimated $32.3K.
  • Johnson & Johnson first reported a position in Gyre Therapeutics in Q3 2021 and held it in 9 quarters.
  • Johnson & Johnson's Gyre Therapeutics position peaked at $275K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2023.

Based on Johnson & Johnson's 13F filing for Q4 2023, filed 14 Feb 2024.